BioNexus files $100M shelf, enters $20M ATM with Maxim Group

BioNexus Gene Lab Corp

Enters Equity Distribution Agreement with Maxim Group LLC to sell up to $20M of common stock via ATM.
Filed S-3 shelf registration registering up to $100M of securities, not yet effective.
Proceeds to support growth initiatives: term sheets with Fidelion Diagnostics (VitaGuard MRD) and BirchBioMed Inc.
Company focuses on precision diagnostics, gene-based technologies in Asia and U.S.

item 1.01item 7.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.